James C. Shehan is quoted in an article discussing high drug prices and Congressional activity aimed at driving down rising costs. In The American Journal of Managed Care, his interview with The Center for Biosimilars is referenced, with Shehan commenting that the U.S. Congress has been “all talk and no action” for the last decade. States, however, Shehan notes, have taken concrete action on drug pricing, with almost every state having considered some kind of proposal and a number of laws enacted.